← Eichor
Condition: Peripheral T Cells Lymphoma Ptcl Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Peripheral T Cells Lymphoma Ptcl

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL
Phase 3 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT05931263Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
Phase 1 · 10 location(s) · SciTech Development, Inc. · NCT04234048Go-CHOP as the Frontline Therapy for PTCL
Phase 2 · 1 location(s) · Henan Cancer Hospital · NCT05963347Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07372352Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma
Phase 2 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT06151106Genotype-guided Treatment in Newly Diagnosed PTCL
Phase 1/Phase 2 · 1 location(s) · Ruijin Hospital · NCT05675813Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL
Phase 2 · 6 location(s) · University of Virginia · NCT04747236A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL
Phase 1/Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06855823Linperlisib Combined With Chidamide in Patients With PTCL
Phase 1/Phase 2 · 6 location(s) · Yanyan Liu · NCT06421948Chidamide Combined With Brentuximab Vedotin Regimen for CD30+ PTCL Patients
NA · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07074457Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Phase 2 · 6 location(s) · Great Novel Therapeutics Biotech & Medicals Corporation · NCT05833724To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
Phase 3 · 69 location(s) · Acrotech Biopharma Inc. · NCT06072131Bendamustine Combined With Chidamide and Lenalidomide for Relapsed and Refractory PTCL Patients
NA · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07072221RIC With Thiotepa Combined With Bu/Flu/Ara-C in Allo-HSCT for Relapsed or Refractory PTCL.
Phase 2 · 1 location(s) · Xianmin Song, MD · NCT06468267Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma
Phase 3 · 1 location(s) · Fudan University · NCT07300514Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Pe
Phase 2 · 1 location(s) · Liling Zhang · NCT05976997Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Speci
Phase 3 · 34 location(s) · Corvus Pharmaceuticals, Inc. · NCT06561048Golidocitinib Plus CHOP in Newly Diagnosed PTCL
Phase 1/Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT06739265Allo-HSCT Vs. Auto-HSCT for PTCL Patients With PR After First-line Systemic Therapy : A Prospective, Multicenter, Cohort
Phase N/A · 1 location(s) · Shanghai General Hospital, Shanghai Jiao Tong University Sch · NCT07253129Polyspecific Antibodies in Lymphoproliferative T-cell Disorders
Phase 1/Phase 2 · 8 location(s) · Xenothera SAS · NCT06495723A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Phase 1 · 22 location(s) · Incyte Corporation · NCT07195916Allo-PBSCT as the First-line Treatment for Patients With the High-risk PTCL
NA · 1 location(s) · Shanghai General Hospital, Shanghai Jiao Tong University Sch · NCT06509945AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
Phase 1/Phase 2 · 37 location(s) · AstraZeneca · NCT06137144Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy
Phase 3 · 1 location(s) · Shanghai General Hospital, Shanghai Jiao Tong University Sch · NCT07414758A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT07055477To Observe the CD7-targeted CAR-T Therapy in the Treatment of r/r PTCL
Phase 1 · 1 location(s) · Peking University People's Hospital · NCT07143929A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
Phase 3 · 51 location(s) · Dizal Pharmaceuticals · NCT07234162A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas
Phase 1/Phase 2 · 20 location(s) · The Lymphoma Academic Research Organisation · NCT07018752A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Phase 1/Phase 2 · 1 location(s) · Genfleet Therapeutics (Shanghai) Inc. · NCT05934513Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Phase 1/Phase 2 · 1 location(s) · Jonsson Comprehensive Cancer Center · NCT06810778
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.